E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Benign prostatic hyperplasia BPH is a non malignant enlargement of the prostate due to cellular hyperplasia of both glandular and stromal elements. As the prostate increases in size it may exert pressure on the lumen of the prostatic urethra, resulting in a gradual obstruction to urine flow. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 6.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10004446 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to test the hypothesis that the effectiveness of silodosin 8 mg given once daily for 12 weeks is superior to placebo and non-inferior to tamsulosin 0.4 mg given once daily for the relief of symptoms of BPH as measured by a baseline to endpoint change in the total score questions 1 to 7 of the International Prostate Symptom Score-1 IPSS-1 . |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives are to compare the effectiveness and safety of silodosin to tamsulosin in a baseline to endpoint change in the following parameters irritative symptoms subscore; obstructive symptoms subscore; QoL due to urinary symptoms question 8 of IPSS-1 ; maximum urine flow Qmax ; percentage of treatment responders by IPSS-1 and by Qmax; and evaluation of adverse events, vital signs, ECGs, clinical laboratory tests and physical examinations. In a further step, as an optional extension to this protocol, the objective of the long-term open-label study period is to obtain long-term 6 and 12 months safety data on silodosin 8 mg given as once daily treatment. Efficacy parameters will be also evaluated during long-term treatment. |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1. Male subjects aged 50 years or older; 2. Presence at Visits 2 start of placebo run-in and 3 baseline , of an IPSS-1 score of 13; 3. Presence of less than 25 decrease of the IPSS-1 score between Visit 2 start of placebo run-in and Visit 3 baseline ; 4. Presence at Visits 2 start of placebo run-in and 3 baseline , of bladder outlet obstruction, as defined by a Qmax peak urine flow rate between 4 and 15 mL/sec, with a minimum voided volume of 125 mL; 5. Presence of a satisfactory compliance to study medication 80-120 at Visit 3 baseline ; 6. Able to comply with protocol procedures; 7. Able to give written informed consent before beginning any investigational procedures. |
|
E.4 | Principal exclusion criteria |
1.Post void bladder residual vol. of greater than 250mL; 2.Intravesical obstruct. from any cause other than BPH ; 3.Bladder calculi; 4.History of, or current, neurogenic bladder and other conditions that may affect bladder function; 5.History of any type of procedure in the past that is considered intervention for BPH or bladder neck obstruction; 6.An active urin. tract inf., or a history of recurrent urin. tract inf.; 7.Current prostatitis or a diagnosis of chronic prostatitis; 8.History of urinary retention, from a cause other than BPH, within the past 3 months; 9.History of prior prostate cancer, or prostate cancer as suspected by TRUS, DRE or clinical acumen. Subjects with a PSA greater than 10.0 ng/ml will be excluded. Subjects with a PSA between 4.0 and 10.0 should have prostate cancer ruled out to the satisfaction of the clinical Investigator with appropriate documentation of the physician s assessment; 10.History of prior invasive bladder cancer; 11.Prior radiation to the pelvis regardless of the reason or dosage of radiation; 12.Bladder catheterization or bladder or prostate instrumentation within the past 30 days; 13.History of, or current significant postural hypotension, and/or have experienced significant postural hypotension upon initiating therapy with an alfa-blocker.; 14.Clinical significant cardiovascular and cerebrovascular disease in the last 6mo; 15.Poorly controlled diabetes HbA1c 8 ; 16.Renal insuff. serum creatinine 2.0 mg/dL ; 17.Liver insuff. any LFT 2xULN ;18.Hematuria which has not been appropriately evaluated to determine safe subject participation;19.Rec. episodes of dizziness, vertigo, or loss of consciousness; 20.Pelvic surgery for malignancy or bowel resection; 21.History or current evidence of drug or alcohol abuse within the last 12 months; 22.History of allergy to alfa-blockers, or to any of the inactive agents used in this formulation; 23.Uncontrolled hypo- or hyperthyroidism; 24.Participation in a study involving the admin. of an inv. compound within the past 30days, or within 5times the half life of the prior inv. drug, whichever is longer; 25.Any subject, in the investigator s opinion, not considered suitable for enrolment; 26.History of inadequate clin. resp. to the use of alfa-blockers spec. for the release of BPH symptoms; 27.Receiving med. after V1,which preclude safe part. in the study or that may produce a confounding effect on the var.under study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The International Prostate Symptom Score IPSS-1 is a 8-item questionnaire designed to quantify the symptoms encountered most frequently with BPH and it has become the international standard. For questions 1-6, questions are graded on a 6-point scale with 0 not at all and 5 almost always . For question 7, the descriptors are 0 none to 5 5 or more times . The total score questions 1 to 7 is a sum of each question s result. The primary efficacy parameter is based on this total score. The standard IPSS-1 see Appendix 14.8 of the study protocol will be assessed at visit 2 entry criteria , visit 3 entry criteria and baseline value and at visit 6, 7 and 8. Validated local translations will be used in each country. A time-adapted modified version asking questions about symptoms observed in the previous week instead of the previous month will be used at Visit 4 and 5, because these visits occur after 7 and 14 days of therapy, respectively see Appendix 14.8 of the study protocol . For subjects entering the Open-Label Extension period, IPSS-1 standard version will be also assessed at visit 10, 11 and 12. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Optional open label phase |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 9 |